Fibronex

Fibronex is an off-the-shelf cell therapy candidate being developed by ViferaXS for the treatment of bladder cancer and various solid tumors. Utilizing ViferaXS's T cell activator technology, Fibronex is designed as an allogeneic (off-the-shelf) treatment, aiming to provide a more accessible alternative to patient-specific autologous cell therapies. The program is currently in the preclinical stage of development. While the specific molecular targets for Fibronex have not been publicly disclosed, the therapy is intended to harness the immune system's T cells to recognize and eliminate cancerous cells within solid tumor environments.